Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record.

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

Open access
Lublin, Fred D., Cofield, Stacey S., Cutter, Gary R., Conwit, Robin, Narayana, Ponnada A., Nelson, Flavia, Salter, Amber R., Gustafson, Tarah, Wolinsky, Jerry S., for the CombiRx Investigators · 2013 · Annals of Neurology

Abstract

Objective: A double‐blind, randomized, controlled study was undertaken to determine whether combined use of interferon β‐1a (IFN) 30μg intramuscularly weekly and glatiramer acetate (GA) 20mg daily is more efficacious than either agent alone in relapsing–remitting multiple sclerosis. Methods: A total of 1,008 participants were randomized and followed until the last participant enrolled completed 3 years. The primary endpoint was reduction in annualized relapse rate utilizing a strict definition of relapse. Secondary outcomes included time to confirmed disability, Multiple Sclerosis Functional Composite (MSFC) score, and magnetic resonance imaging (MRI) metrics. Results: Combination IFN + GA was not superior to the better of the single agents (GA) in risk of relapse. Both the combination therapy and GA were significantly better than IFN in reducing the risk of relapse. The combination was not better than either agent alone in lessening confirmed Expanded Disability Status Scale progression or change in MSFC over 36 months. The combination was superior to either agent alone in reducing new lesion activity and accumulation of total lesion volumes. In a post hoc analysis, combination therapy resulted in a higher proportion of participants attaining disease activity‐free status (DAFS) compared to either single arm, driven by the MRI results. Interpretation: Combining the 2 most commonly prescribed therapies for multiple sclerosis did not produce a significant clinical benefit over 3 years. An effect was seen on some MRI metrics. In a test of comparative efficacy, GA was superior to IFN in reducing the risk of exacerbation. The extension phase for CombiRx will address whether the observed differences in MRI and DAFS findings predict later clinical differences. ANN NEUROL 2013;73:327–340

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.23863

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 203

Metadata

Authors
Lublin, F. D., Cofield, S. S., Cutter, G. R., Conwit, R., Narayana, P. A., Nelson, F., Salter, A. R., Gustafson, T., Wolinsky, J. S., & for the CombiRx Investigators
Venue
Annals of Neurology
Publisher
Wiley
Published
2013-03
Volume
73
Issue
3
Pages
327-340
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W1512495229
Cited by
203
References
0
FWCI
22.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized study combining interferon and glatiramer acetate in multiple sclerosis. https://app.cochat.ai/papers/10.1002/ana.23863
The paper
Lublin, F. D., Cofield, S. S., Cutter, G. R., Conwit, R., Narayana, P. A., Nelson, F., Salter, A. R., Gustafson, T., Wolinsky, J. S., & for the CombiRx Investigators. (2013). Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of Neurology. https://doi.org/10.1002/ana.23863

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.